ST JOSEPH, Mich., Nov. 22, 2010/PRNewswire/ -- GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, and Agilent Technologies, Inc., the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications, announced today that they have integrated Agilent’s GeneSpring Bioinformatics Solution with MetaCore.
GeneSpring GX 11.5, released today, introduces a multi-omics microarray and mass-spectrometry based analysis suite to handle transcriptomics, genomics, metabolomics and proteomics data in one application. GeneSpring GX 11.5 includes a direct connection to the MetaCore pathway analysis engine that allows users to seamlessly upload expression data analyzed in GeneSpring for pathway analysis in MetaCore. This connection is part of every expression workflow in GeneSpring, allowing automatic experiment creation and entity annotation in MetaCore.
“We are very pleased to integrate GeneGo’s MetaCore pathway analysis capabilities into GeneSpring’s expression workflows,” said Michael Janis, GeneSpring Product Manager at Agilent Technologies. “Our users have access to industry-leading analysis and visualization tools within GeneSpring and the ability to combine statistical analysis in GeneSpring with MetaCore’s strengths in pathway analysis will enable a deeper understanding of their research in a biological context.”
“This will allow our joint customers to seamlessly work with omics data in the context of pathways,” said Julie Bryant VP of business development. “MetaCore can concurrently visualize multiple types of data and will be able to take advantage of this new functionality in GeneSpring which will be very helpful to our joint customers.”
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscoveryplatform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 6.3, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.3 is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.
For more information, please visit the company’s web site at www.genego.com.
SOURCE GeneGo, Inc.
